Hongkongers Start Receiving BioNTech Jabs
"); jQuery("#212 h3").html("
"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1579748_1_20210310182932.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1579748-20210310.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1579748-20210310.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-03-10 HKT 13:14
Share this story
Hong Kong on Wednesday began inoculating people against coronavirus with Germany's BioNTech vaccine, with some of those first in the queue saying they believe it will be safer and more effective than the Sinovac jab also available.
Seven centres – in Sai Ying Pun, Sai Wan Ho, Kowloon Tong, Kwun Tong, Lai Chi Kok, Sheung Shui and Yuen Long are now providing the BioNTech jabs, for priority groups at first.
Many of those who had booked appointments at the Kowloon Tong centre on Wednesday were foreign residents. People RTHK spoke to said they were confident about receiving the vaccine.
“I’m not afraid at all. Not at all. Because they have a full medical report published, and millions and millions of people abroad have already taken the jabs. I know there are no serious side effects,” said an 80-year-old man.
A pharmacist surnamed Lam agreed that any side effects should be mild.
"From overseas experience, this vaccine is also used in high risk groups, for the elderly and also people with chronic diseases. I have confidence in this vaccine," she said.
A 76-year-old man surnamed Azim said he was not concerned about having an adverse reaction to the jab.
“I’m in good health, so no problem for me,” he laughed.
“We were told that Pfizer/BioNTech is the best. Pfizer has more efficacy,” he added.
A man surnamed Lam, meanwhile, said he didn't want to take the Sinovac jab after seeing news reports about deaths and hospitalisations among people who had received it.
“I’m not confident about it. You can see on the news, one case after another. If I’m unlucky, I might be one of them,” he said.
Authorities and experts have said they don't believe the recent deaths were linked to the Sinovac jabs, and some of those taking the BioNTech vaccine on Wednesday said they would have preferred to get the China-made vaccine, but couldn't get an appointment slot.
Most of the people RTHK spoke to said they felt fine after having the BioNTech jab. They will need to take a second dose after three weeks.
HashKey Capital Partners With Tiantu AM To Explore Virtual Asset Funds
HashKey Capital has signed a memorandum of strategic collaboration with Tiantu Asset Management (Tiantu AM), a wholly o... Read more
You Can Now Make Alipay Payments With AR Glasses
RayNeo and Ant Group have announced a partnership to develop digital payment solutions for global use. The collaboratio... Read more
JICA Goes Live With Finastras Loan IQ In First Japan Deployment
Finastra has announced that the Japan International Cooperation Agency (JICA) has gone live with its Loan IQ platform. ... Read more
Japan Set To Approve First Yen-Backed Stablecoin
Japan’s Financial Services Agency (FSA) is preparing to approve the issuance of the country’s first yen-backed stab... Read more
Indonesia And China Begin Trials For Cross-Border QRIS Payments
Bank Indonesia (BI) and the People’s Bank of China (PBOC) have begun a series of trials for cross-border QR code paym... Read more
ANZ Appoints Ender Tanar As Japan Country Head
ANZ, headquartered in Melbourne, Australia, announced the appointment of Ender Tanar as Country Head for Japan, reporti... Read more